Nova in Silico Overview
- Year Founded
-
2010
- Status
-
Private
- Employees
-
50
- Latest Deal Type
-
2ndary - Private
- Investors
-
2
Nova in Silico General Information
Description
Developer of clinical trial simulation technology designed to optimize drug development processes. The company's platform integrates disease modeling, virtual patient simulations, and protocol design tools to predict clinical outcomes, refine trial parameters, evaluate treatment effects across diverse populations, and reduce reliance on human subjects, enabling pharmaceutical and biotech organizations to improve efficiency and lower costs in clinical research.
Contact Information
Website
www.novainsilico.aiCorporate Office
- 18 Rue Felix Mangini
- 69009 Lyon
- France
Corporate Office
- 18 Rue Felix Mangini
- 69009 Lyon
- France
Nova in Silico Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Secondary Transaction - Private | 01-Jan-2025 | Completed | Generating Revenue | |||
| 7. Angel (individual) | 06-Jun-2024 | Completed | Generating Revenue | |||
| 6. Later Stage VC (Series A2) | 16-Feb-2021 | Completed | Generating Revenue | |||
| 5. Grant | 19-Jan-2021 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A) | 09-Jan-2020 | Completed | Generating Revenue | |||
| 3. Grant | 13-Jun-2015 | Completed | Generating Revenue | |||
| 2. Early Stage VC | 18-Aug-2014 | $469K | $656K | Completed | Startup | |
| 1. Early Stage VC | 18-Jun-2010 | $186K | $186K | Completed | Startup |
Nova in Silico Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| A Shares | ||||||||
| Ordinary | ||||||||
| BSA 2015-1 | ||||||||
| Ordinary | ||||||||
| ABSA 2014-1 | 8,358 | $50.67 | $50.67 | 1x | $50.67 | 5.32% | ||
| Ordinary | 14,813 | $12.44 | $12.44 | 1x | $12.44 | 9.42% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Nova in Silico Comparisons
Industry
Financing
Details
Nova in Silico Competitors (5)
One of Nova in Silico’s 5 competitors is InSilicoTrials, a Venture Capital-Backed company based in Trieste, Italy.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| InSilicoTrials | Venture Capital-Backed | Trieste, Italy | ||||
| Certara | Formerly PE-Backed | Radnor, PA | ||||
| QuantHealth | Venture Capital-Backed | Tel Aviv, Israel | ||||
| esqLABS | Corporation | Saterland, Germany | ||||
| Vantage Research | Corporation | New York, NY |
Nova in Silico Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Nova in Silico Patents
Nova in Silico Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2011238099-A1 | Computer based system for predicting treatment outcomes | Inactive | 07-Apr-2010 | ||
| CA-2832355-A1 | Computer based system for predicting treatment outcomes | Inactive | 07-Apr-2010 | ||
| EP-2556460-A1 | Computer based system for predicting treatment outcomes | Inactive | 07-Apr-2010 | ||
| US-20130041683-A1 | Computer based system for predicting treatment outcomes | Inactive | 07-Apr-2010 | ||
| US-20180039726-A1 | Computer based system for predicting treatment outcomes | Inactive | 07-Apr-2010 | G16B5/00 |
Nova in Silico Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Nova in Silico Investors (2)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Sanofi | Corporation | Minority | ||
| Bpifrance | Sovereign Wealth Fund |
Nova in Silico FAQs
-
When was Nova in Silico founded?
Nova in Silico was founded in 2010.
-
Where is Nova in Silico headquartered?
Nova in Silico is headquartered in Lyon, France.
-
What is the size of Nova in Silico?
Nova in Silico has 50 total employees.
-
What industry is Nova in Silico in?
Nova in Silico’s primary industry is Discovery Tools (Healthcare).
-
Is Nova in Silico a private or public company?
Nova in Silico is a Private company.
-
What is Nova in Silico’s current revenue?
The current revenue for Nova in Silico is .
-
How much funding has Nova in Silico raised over time?
Nova in Silico has raised $9.3M.
-
Who are Nova in Silico’s investors?
Sanofi and Bpifrance have invested in Nova in Silico.
-
Who are Nova in Silico’s competitors?
InSilicoTrials, Certara, QuantHealth, esqLABS, and Vantage Research are competitors of Nova in Silico.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
